951 - Reponse to cabazitaxel in the postchemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Prostate Cancer
Presenter Laurence Albiges
Authors L. Albiges1, S. Le Moulec2, Y. Loriot1, M. Gross Goupil3, T. De La Motte Rouge4, A. Guillot5, K. Fizazi6, C. Massard7
  • 1Medical Oncology, Institut de cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 2Oncologie Medicale, Hopital du Val de Grace Val de Grace, 75230 - Paris CEDEX 5/FR
  • 3Medical Oncology, Hôpital Saint-André, CHU bordeaux, Bordeaux/FR
  • 4Medical Oncology, Salpétrière Hospital, Paris/FR
  • 5Medical Oncology, INSTITUT DE CANCÉROLOGIE DE LA LOIRE, 42271 - SAINT PRIEST EN JAREZ CEDEX/FR
  • 6Department Of Medical Oncology, Institute Gustave Roussy, FR-94805 - Villejuif/FR
  • 7Sitep, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif CEDEX/FR

Abstract

Background

Cabazitaxel (a tubulin-binding taxane chemotherapy) and Abiraterone acetate (AA) have recently been approved for patients with metastatic castration resistant prostate cancer (CRPC) following docetaxel chemotherapy. Recent studies suggest that taxane also impact AR signalling such as AA, and could explain cross-resistance between new hormonal manipulations and taxane chemotherapy. The aim of this study is to evaluate the antitumor activity of cabazitaxel in patients whose disease progresses on AA.

Patients and methods

Eligible pts had metastatic CRPC and progression disease after docetaxel and AA. All the patients received cabazitaxel 20 mg/m2 every 3 weeks + prednisone 5 mg BID. Radiological response by RECIST, PSA response by PSAWG2 criteria and symptomatic benefit were evaluated.

Results

In the 38 pts treated with cabazitaxel, baseline median age was 69 years (48-81), ECOG PS 0 or 1 in 90% of pts, and median PSA 350 ng/ml (3,75-9150). Bone, lymph nodes and visceral metastases were present in 30 pts (90%), 5 pts (15%), and 5 pts (15%) respectively. An average of 4 cycles of cabazitaxel (range 1-9) were given, 85% patients received granulocyte-colony stimulating factor prophylaxis from cycle 1, and 15 pts (39%) continue on cabazitaxel at the time of safety analysis. Out of 38 patients, 16 patients stopped before completing the full course, 15 of these patients were due to disease progression. No major toxicities were noticed. Of 32 patients with PSA data available, 18 (56%) pts have had a 50% or greater PSA decline, 5 pts (15%) have had a partial response.

Conclusion

Cabazitaxel appears active and well tolerated in pts with metastatic CRPC who are resistant to AA. Our data do not provide any evidence for cross-resistance between these two agents. Final results will be reported.

Disclosure

All authors have declared no conflicts of interest.